We report here the results of the first whole of population-based screening program for Lynch syndrome using two laboratory-based methods. Our findings indicate that approximately two thirds of all Lynch syndrome cases amongst colorectal cancer patients are being identified in the state of Western Australia. We propose that a reference laboratory for microsatellite instability testing and the position of a Lynch coordinator are critical to the success of population-based screening programs for this familial cancer syndrome. this has increased to an average of 8 LS cases diagnosed annually. Based on our experience in WA, we propose three key elements for successful population-based screening of LS. First, for all younger CRC patients, reflex IHC testing should be carried out in accredited pathology services with ongoing quality control. Second, a state-or region-wide reference laboratory for MSI testing should be established to confirm abnormal or suspicious IHC test results and to exclude sporadic cases by carrying out BRAF mutation or MLH1 methylation testing. Finally, a state or regional LS co-ordinator is essential to ensure that all appropriate cases identified by laboratory testing are referred to and attend a Familial Cancer Clinic for follow up and germline testing.
Immunohistochemistry (IHC) for loss of MMR protein expression was performed in routine pathology laboratories while MSI was detected in a reference molecular pathology laboratory.
Information on germline mutations in MMR genes was obtained from the state's single familial cancer registry. Prior to the introduction of routine laboratory-based screening, an average of 2-3 cases of LS were diagnosed each year amongst WA CRC patients. Following the implementation of IHC and/or MSI screening for all younger (<60 years) CRC patients, this has increased to an average of 8 LS cases diagnosed annually. Based on our experience in WA, we propose three key elements for successful population-based screening of LS. First, for all younger CRC patients, reflex IHC testing should be carried out in accredited pathology services with ongoing quality control. Second, a state-or region-wide reference laboratory for MSI testing should be established to confirm abnormal or suspicious IHC test results and to exclude sporadic cases by carrying out BRAF mutation or MLH1 methylation testing. Finally, a state or regional LS co-ordinator is essential to ensure that all appropriate cases identified by laboratory testing are referred to and attend a Familial Cancer Clinic for follow up and germline testing.
INTRODUCTION
Lynch syndrome (LS), formerly known as hereditary non-polyposis colorectal cancer (HNPCC), is an autosomal dominant condition caused by germline mutations in DNA mismatch repair (MMR) genes, most commonly MLH1, MSH2, MSH6 and PMS2. 1, 2 Tumours from LS cases have a defective DNA mismatch repair system, leading to ubiquitous small deletions and insertions in DNA repeat regions (microsatellites) resulting in microsatellite instability (MSI). MSI is almost always accompanied by the loss of expression of MMR proteins that can be readily detected using immunohistochemical (IHC) methods. These two molecular features are also observed in approximately 10% of sporadic (non-hereditary) colorectal cancer (CRC), meaning they are not completely specific markers for the presence of LS. However, sporadic microsatellite-unstable (MSI+) CRC contains mutations in the BRAF oncogene and often shows methylation of the MLH1 gene promoter, whereas MSI+ CRC from LS patients does not. 3, 4 Hence, the BRAF mutation and MLH1 methylation tests can be used to distinguish sporadic from LS-associated MSI+ CRC.
In addition to CRC, LS is also associated with an increased risk of endometrial, small bowel, urothelial, gastric, ovarian and other cancer types. Although some authors have reported that LS may be responsible for up to 3% of CRC, 5, 6 population data derived from MSI screening suggested this may be closer to 1%. [7] [8] [9] 11 Regardless of the exact prevalence, the identification of mutation carriers is critical because it allows early and increased surveillance for cancer, the option of prophylactic surgery and the ability to clarify risk status in the extended family. Regular screening by colonoscopy has been demonstrated to reduce both the incidence and mortality of CRC in LS patients and affected family members. 12 Until recently, patients at risk for LS were identified through the use of clinical criteria such as the Amsterdam and Bethesda guidelines that rely heavily on obtaining a detailed family history. 13, 14 These guidelines have a relatively low sensitivity for the detection of LS and their implementation in routine clinical practice is generally acknowledged as having been quite poor. In addition there is evidence that clinicians do not elicit a sufficient family history 15 and even when they do referrals are inappropriately low. 16 This has led to repeated calls for the introduction of a laboratory-based (MSI and IHC) screening approach that avoids the need to obtain and validate a detailed family history of cancer.
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We previously reported the results of a large retrospective study carried out in the state of Western Australia (WA) to detect LS amongst CRC patients aged <60 years at diagnosis and in the absence of any information on family cancer history. 9 This work established that MSI screening followed by testing for BRAF mutation in the MSI+ cases, referred to as "red 
METHODS

Colorectal cancer patients
WA has a population of 2. 
Follow-up of red flag cases
Treating clinicians informed red flag patients of the laboratory test result and the possible implications in terms of LS. Patients were advised to attend GSWA for counselling and possible germline testing. For patients who gave consent, germline testing for mutations in the MMR genes MLH1, MSH2, MSH6 and PMS2 was carried out as described previously.
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RESULTS
The first case of LS was identified by GSWA in 1994, shortly after pathogenic mutations in MMR genes were identified as the cause of what was then known as HNPCC. Over the ensuing 11 years until 2004, from 1-4 new cases were identified each year ( Figure 1 ). This was recognized at the time as being less than expected, considering that the annual incidence of CRC in WA was approximately 1,000 cases during this period 22 and assuming that LS is responsible for 1-3% of all CRC.
Beginning in 2003, retrospective screening of archival CRC tissues using MSI testing was performed in an attempt to identify previously unrecognized LS cases. The first pilot study involved the screening of 1,020 CRC diagnosed at a single hospital (Sir Charles Gairdner Hospital) from 1990-1999 inclusive. 24 The second study involved the screening of almost 1,400 CRC patients aged <60 years who were diagnosed from 2000-2007 inclusive. 9 This was estimated to have captured 85% of the state's CRC cases in that age group reported to the WA Cancer Registry during the 7 year study period. Red flag cases (MSI+, BRAF wildtype) identified by these two studies were followed up and offered genetic testing, mutations. In addition, the retrospective MSI screening of CRC identified 3 families with epigenetic mutations in MLH1 and one family with an EPCAM germline mutation. One of the families with an MLH1 epimutation has been described elsewhere. 25 A further 177 mutation positive family members had also been identified by predictive testing (Figure 2) , giving a total of 292 mutation carriers identified thus far in WA.
Compared to the InSiGHT database of 3,072 reported MMR gene mutations, 26 the WA LS cohort displayed a significantly higher proportion of MSH2 mutations (P=0.005) but a lower proportion of MSH6 mutations (P=0.03) (Figure 3) . No significant differences were apparent for the relative frequencies of MLH1 and PMS2 mutations between these two cohorts.
DISCUSSION
There have been numerous reports on the use of MSI and IHC screening for the detection of LS in CRC cohorts. 2, 6, 7, 8, 11, 27 The present study follows on from our earlier screening of retrospective CRC cases 9, 24 and is to our knowledge the first to use laboratory tests on a to the increase in, and ageing of the population. 22 However, this increase in CRC incidence cannot account for the more than 3-fold increase in the rate of LS diagnosis between the first and third phases (2.6 vs 8.4 cases per year). Many of the screen-detected LS patients did not report a family history of cancer sufficient to meet the Amsterdam or Bethesda criteria and hence it is unlikely they would have been identified without laboratory screening tests. We conclude from our results that routine MSI and IHC screening of CRC has led to a marked increase in the identification of LS in WA.
We cannot be sure that all the LS cases amongst WA CRC patients are now being detected following the implementation of routine IHC and MSI screening. This is because of the uncertainty surrounding the contribution made by LS to the overall incidence of CRC.
Hampel et al reported a prevalence of 2.8% for LS in their Ohio University study of 1,566 CRC patients. 5 A pooled analysis of 4 large cohorts that included the Ohio series reported an MMR gene mutation frequency of 3.1%. 6 However, two other large MSI-based screening studies comprising more than 1,000 CRC patients each reported frequencies of 0.86% 7 and 0.9%, 8 consistent with our earlier estimate of 0.83%. 9 A recent clinic-based study estimated the germline mutation frequency amongst 245 consecutive cases of MMR deficient CRC was 7.1%. 11 Since the incidence of MMR deficient tumours in their overall CRC cohort was 11.7%, this implies the prevalence of LS was 0.83%. If we therefore assume that 0. There are likely to be several reasons as to why only two thirds of the 12 expected annual LS cases are being identified, even with the introduction of laboratory-based screening.
Many of these factors were also highlighted in a recent clinic-based study. 27 First, only CRC patients aged <60 years were screened for MSI in the retrospective study of 2000-2006 cases. 9 Although the large majority of LS patients are diagnosed with CRC at an early age (mean of 43 years in our cohort), there are certainly older patients who would not be detected using an age threshold of <60 years for screening. Second, we cannot be certain that all pathology This may be attributable to greater awareness by treating clinicians of the need to refer red flag cases to GSWA, as well as the presence of an LS coordinator in the state of Western Australia. Second, a state-or region-wide reference laboratory for MSI testing is required to confirm all abnormal or equivocal IHC test results identified in the first screen by pathology service providers. This is critical in order to avoid large numbers of cases with false positive IHC results from being referred to familial cancer clinics for follow up. The quality of IHC testing and its interpretation vary between laboratories and this may be due to recognized factors such as tissue fixation and heterogeneity of staining. 28 Compared to IHC, the MSI test is in our experience less prone to errors of interpretation and is more readily standardized. In addition to MSI testing, the reference molecular pathology laboratory should be capable of performing BRAF mutation and/or MLH1 methylation assays so that sporadic MSI+ cases can be excluded, 3, 4 again preventing many unnecessary referrals to familial cancer clinics.
Although IHC for the detection of BRAF mutations has been suggested, a recent study found this approach cannot be used as a surrogate to genotyping due to inadequate sensitivity. 
